Octreotide Teva (Octreotide Acetate)

Octreotide Teva is a somatostatin analogue that modulates neuroendocrine activity in several disease pathways.

• Acromegaly: reduces excessive growth hormone secretion and helps control serum IGF‑1 levels.
• Neuroendocrine tumors (carcinoid syndrome): alleviates flushing and diarrhea by inhibiting vasoactive peptide release.
• Preventing postoperative postoperative pancreatic fistula: decreases pancreatic secretions after major abdominal surgery.
• Control of severe hypoglycaemia related to insulinoma or sulfonylurea overdose.
• Management of refractory gastrointestinal bleeding associated with portal hypertension.

• Octreotide binds with high affinity to somatostatin receptors (SST‑1, SST‑2 and SST‑3) on target cells, inhibiting adenylate cyclase activity and reducing cyclic AMP formation. This receptor activation suppresses the release of several hormones and peptides—including growth hormone, insulin, glucagon, gastrin and vasoactive intestinal peptide—thereby modulating endocrine and exocrine secretory pathways.

Octreotide may elicit a range of adverse reactions, most of which are dose‑dependent and reversible upon discontinuation.

Common Side Effects

• Nausea and vomiting
• Abdominal pain or cramping
• Diarrhea or loose stools
• Injection site erythema or discomfort
• Headache
• Mild hyperglycaemia or hypoglycaemia

Serious or Rare Side Effects

• Gallbladder sludge or gallstones
• Severe hyperglycaemia requiring insulin therapy
• Acute pancreatitis
• Cardiac arrhythmias
• Anaphylactic or severe hypersensitivity reactions
• Hepatic dysfunction with elevated transaminases

Octreotide should be used with careful clinical monitoring and appropriate patient education.

• Renal impairment: adjust monitoring frequency as drug clearance may be reduced.
• Hepatic dysfunction: observe for altered metabolism and potential accumulation.
• Diabetes mellitus: monitor blood glucose closely, as the drug can cause hyper‑ or hypoglycaemia.
• Cardiac disease: watch for brady‑cardia or arrhythmias, especially in patients with pre‑existing conduction abnormalities.
• Pregnancy: evaluate risk‑benefit ratio; use only if clearly needed.
• Store at 2-8°C: keep refrigerated (do not freeze) and protect from light ; ensure the vial remains in its original pack.

Octreotide can interact with several concomitant medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Cyclic peptide c‑    ");

Moderate "); - - - - - - - - - - - - - - - - - - - - - - - - - - - -

• \n